Genetics for Smarter Medication Management

Admera Health believes in the promise of precision medicine to help improve patient outcomes while reducing costs.

Whether it is for a hospital, healthcare system, payer, PBM, or a self-insured organization, Admera Health offers end-to-end pharmacogenomics (PGx) solutions.
  • PGxOne™ Plus for comprehensive end-to-end PGx testing
  • PGx laboratory services
  • PGx interpretative services
Contact Us

The role of pharmacogenomics testing in some of the largest challenges associated with costs facing healthcare organizations:

Reducing Adverse Drug Reactions: Estimations place adverse drug reactions (ADRs) as the fourth leading cause of death. For every dollar spent on prescription drugs an additional 50% is spent on treating ADRs

Patient/Employee Experience: Targeting the right medical intervention to the right patient delivering impactful outcomes. Tailored medication management programs have been shown to increase patient compliance

Provider Engagement: Making evidence-based decisions allows providers to improve the quality of patient care, aligning care standards to the highest level of PGx evidence

Operational Effectiveness: In addition to reducing ADRs, avoid paying for ineffective care, reduce readmission rates, improve care coordination, and collaboration

Employee Health: PGx testing can help maintain employee health, which can decrease workforce healthcare costs, and improve employee productivity

The Admera Health Solution:

PGxOne™ Plus is designed to cover the most technically difficult to sequence gene variants associated with PGx:

PGxOne™ Plus genotypes by Next Generation Sequencing (NGS) technology, which can more robustly detect a broader spectrum of variant types, has superiority in scalability, speed, and resolution; and is able to detect single nucleotide polymorphisms (SNP), insertions & deletions (Indels), and copy number variants (CNV) in a single assay.

Admera Health’s knowledge base only includes the highest level of PGx evidence: 

Pharmacogenomics gene-drug interactions are tiered based on the medical and scientific evidence available. The FDA, Clinical Pharmacogenomics Implementation Consortium (CPIC), Association of Molecular Pathologists (AMP), College of American Pathologists (CAP), and PharmGKB are the most well-established sources of PGx information.

Admera Health provides biological systems-based annotations: 

In Biology, more than one protein and/or enzyme can work in tandem to perform an action. A drug can require more than one enzyme or protein interaction for it to perform its therapeutic function. It is important to understand the role each protein plays with the medication, what percentage each contributes, and what the combined effect is.
Admera Health has the flexibility to help establish new precision medicine programs or improve existing ones

Admera Health can help develop Population Health initiatives to identify patients most likely to benefit from PGx testing

Online dynamic reporting via RxVision™ and/or customized EHR integration that can include alerts

Multiple logistical options available, including sample type and delivering supplies directly to patients

Contact Us:

Please fill out the form on the right to learn more about Admera Health’s pharmacogenomics solutions.

Alternatively, you may call us directly at 908-222-0533 followed by Option 3 to speak with a member of the Admera Health Business Development Team.

Please fill out the form below to learn more about Admera Health’s pharmacogenomics solutions.

Alternatively, you may call us directly at 908-222-0533 followed by Option 3 to speak with a member of the Admera Health Business Development Team.